EHC

Encompass Health Corp. (EHC) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Encompass Health Corporation is the nation's largest owner and operator of inpatient rehabilitation hospitals (IRFs), operating 176 facilities across 39 states and Puerto Rico as of the reporting date. The company operates a single reportable segment focused on inpatient rehabilitation services.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net operating revenues increased 9.6% in Q2 and 9.3% YTD compared to 2025, driven by volume growth (5.6% discharge increase in Q2) and favorable pricing (3.9% increase in net patient revenue per discharge).
• Profitability: Net income attributable to Encompass Health rose 8.3% in Q2 and 18.7% YTD. Operating margins improved slightly as total operating expenses grew at a slower rate (9.2%) than revenues in Q2.
• Discontinued Operations: A significant non-recurring gain of $16.3 million (after-tax) was recorded in the first half of 2026 from the settlement of litigation regarding the company's former home health and hospice business.
• Investment Gain: The company recorded a $17.5 million pre-tax gain from the sale of its 50% interest in Gamma Knife Center at Barnes-Jewish Hospital.
• Debt Restructuring: The company issued $500 million of 5.875% Senior Notes due 2034 and used proceeds to redeem $400 million of 4.50% Senior Notes due 2028, resulting in a $3.2 million loss on early extinguishment of debt.

Guidance, Outlook, and Risks

• Capital Expenditures: Management expects to spend approximately $920 million to $995 million on capital expenditures for the full year 2026, with $225 million to $240 million designated as nondiscretionary maintenance.
• Dividends and Buybacks: The quarterly dividend was increased to $0.21 per share (payable October 2026). The board approved a new $1.0 billion share repurchase authorization in July 2026; approximately $188 million remained under the prior authorization as of June 30, 2026.
• Regulatory Environment: The company faces ongoing challenges with the CMS Review Choice Demonstration (RCD), which subjects 33 of its IRFs (approx. 11.9% of Medicare claims) to 100% pre-claim or post-payment review. Management notes inconsistent application of standards by Medicare Administrative Contractors (MACs) in Alabama.
• Reimbursement Outlook: The 2027 Final IRF Rule is expected to result in a net 2.3% increase to Medicare payment rates effective October 1, 2026.
• Liquidity: The company maintains a strong balance sheet with approximately $746 million available under its revolving credit facility and no significant debt maturities until 2028.

Investor Verification Checklist

• Discontinued Operations Impact: Verify the sustainability of earnings by excluding the $16.3 million litigation settlement gain and the $17.5 million Gamma Knife sale gain from core operating performance.
• RCD Program Exposure: Assess the potential cash flow impact of the CMS Review Choice Demonstration, particularly regarding the affirmation rates and appeal processes for the 33 affected hospitals.
• Debt Maturity Profile: Confirm the timeline for the new 2034 Notes and the remaining balance of the 2028 Notes following the partial redemption.
• Capital Allocation: Monitor the execution of the new $1.0 billion share repurchase program and the timing of the increased dividend payments.
• Staffing Costs: Review trends in "Salaries and benefits" as a percentage of revenue, noting the company's efforts to reduce contract labor and sign-on bonuses despite industry-wide staffing shortages.